TRANSCRANIAL MAGNETIC STIMULATION THERAPY IN EARLY AND LATE STAGES OF PARKINSON'S DISEASE
Keywords:
Parkinson's disease, DOFA-decarboxylase, genetic, serotonergic, noradrenergic, GAMK-ergic.Abstract
Movement disorders undoubtedly form the basis of the clinical picture of Parkinson’s disease. But there are a number of other clinical signs that aggravate the course of the disease, namely non-motor symptoms. Neurotrophic factors in the nervous system injury today, especially in the study of degeneration of dopaminergic neurons. In particular, there is a growing interest in the gall neurotrophic factor. Rather, they can be used as a predictor of early detection of diseases, as well as to draw conclusions about their consequences.